Home
>
US Stocks
>
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co.
LJPC

La Jolla Pharmaceutical Co. (LJPC)

$3.8111.4%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
3.73
Today Low/High
3.71 / 3.85
52 Week Low/High
$3.35 / $7.85
Market Cap
$105.28M

Company Details

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
Organisation
La Jolla Pharmaceutical Co.
Headquaters
San Diego, California, US
Employees
59
Industry
Health Technology

Discover more

Frequently Asked Questions

What is La Jolla Pharmaceutical Co. (LJPC) share price today?

Can Indians buy La Jolla Pharmaceutical Co. (LJPC) shares?

How can I buy La Jolla Pharmaceutical Co. (LJPC) shares from India?

Can Fractional shares of La Jolla Pharmaceutical Co. (LJPC) be purchased?

What are the documents required to start investing in La Jolla Pharmaceutical Co. (LJPC) stocks?

We are a SEBI registered investement advisor